Guided Therapeutics, Inc.
GTHP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.04 | 0.13 | -0.01 |
| FCF Yield | -13.01% | -22.25% | -15.47% | -20.70% |
| EV / EBITDA | -5.34 | -2.98 | -2.63 | -10.90 |
| Quality | ||||
| ROIC | 77.22% | 197.77% | 541.95% | 96.53% |
| Gross Margin | 28.57% | 36.73% | -523.08% | 24.69% |
| Cash Conversion Ratio | 0.46 | 0.50 | 0.34 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -18.64% | 6.56% | -49.68% | 31.04% |
| Free Cash Flow Growth | 35.91% | -15.71% | 6.04% | 14.39% |
| Safety | ||||
| Net Debt / EBITDA | -0.91 | -0.47 | 0.01 | -2.45 |
| Interest Coverage | -5.53 | -12.44 | -5.73 | -2.05 |
| Efficiency | ||||
| Inventory Turnover | 0.01 | 0.10 | 0.15 | 0.11 |
| Cash Conversion Cycle | -109,124.57 | -8,162.88 | -7,388.39 | -11,029.93 |